ETON vs. ASMB, SBBP, SLGL, GLYC, ORGO, VRCA, AMRN, PGEN, NLTX, and STTK
Should you be buying Eton Pharmaceuticals stock or one of its competitors? The main competitors of Eton Pharmaceuticals include Assembly Biosciences (ASMB), Strongbridge Biopharma (SBBP), Sol-Gel Technologies (SLGL), GlycoMimetics (GLYC), Organogenesis (ORGO), Verrica Pharmaceuticals (VRCA), Amarin (AMRN), Precigen (PGEN), Neoleukin Therapeutics (NLTX), and Shattuck Labs (STTK). These companies are all part of the "medical" sector.
Assembly Biosciences (NASDAQ:ASMB) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.
Assembly Biosciences received 158 more outperform votes than Eton Pharmaceuticals when rated by MarketBeat users. However, 62.22% of users gave Eton Pharmaceuticals an outperform vote while only 59.31% of users gave Assembly Biosciences an outperform vote.
Eton Pharmaceuticals has higher revenue and earnings than Assembly Biosciences.
Assembly Biosciences has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Eton Pharmaceuticals has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500.
Eton Pharmaceuticals has a consensus price target of $9.00, suggesting a potential upside of 153.52%. Given Assembly Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Eton Pharmaceuticals is more favorable than Assembly Biosciences.
Eton Pharmaceuticals has a net margin of 2.66% compared to Eton Pharmaceuticals' net margin of 0.00%. Assembly Biosciences' return on equity of 5.65% beat Eton Pharmaceuticals' return on equity.
In the previous week, Assembly Biosciences had 11 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 12 mentions for Assembly Biosciences and 1 mentions for Eton Pharmaceuticals. Assembly Biosciences' average media sentiment score of 1.87 beat Eton Pharmaceuticals' score of 0.25 indicating that Eton Pharmaceuticals is being referred to more favorably in the news media.
19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 5.1% of Assembly Biosciences shares are held by insiders. Comparatively, 14.9% of Eton Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Eton Pharmaceuticals beats Assembly Biosciences on 13 of the 16 factors compared between the two stocks.
Get Eton Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ETON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eton Pharmaceuticals Competitors List
Related Companies and Tools
